ORLANDO, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN), a clinical late-stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that Dr. Robert Buckheit, Jr. will join the Scientific Advisory Board (“SAB”) of Immune Therapeutics.
”Immune Therapeutics is fortunate to have an individual as capable as Dr. Buckheit helping guide our development and science,” stated Mike Handley, Chief Executive Officer of Immune. He also stated, “As we move through clinical trials and towards commercialization, we will need to further refine our development and technical strategies, and Dr. Buckheit’s expertise and history of developing drugs is a perfect fit with the needs of Immune.”
Dr. Buckheit is the latest of a string of exceptional and distinguished professionals to join the SAB as Immune Therapeutics continues to restructure and strengthen its base of researchers, physicians, public health officials and business leaders, complementing its endeavors to broaden its efforts in emerging markets.
Dr. Buckheit is the Founder, President and CSO of ImQuest BioSciences and the Co-Founder, Executive Vice President and CSO of ImQuest Life Sciences. He has developed and managed infectious disease, inflammatory disease and cancer research programs for commercial, academic and government clients as Director of Infectious Disease Research at both the Southern Research Institute and at TherImmune Research Corporation/Gene Logic Inc. Dr. Buckheit is a member of the Board of Directors of The Weinberg Center for the Performing Arts in Frederick, Maryland and a member of the Scientific Advisory Board of Oyagen, Inc. He has served as President of the International Society for Antiviral Research and as a member of the Editorial Review Board of the journal, Antiviral Research.
Having worked in the preclinical development of anti-infective agents since 1989, Dr. Buckheit has led the development of dozens of compounds to the IND stage of development, and has authored over 200 peer-reviewed manuscripts throughout his career. Dr. Buckheit received a B.S. in Biology from Lehigh University in 1982, a Ph.D. in Microbiology and Immunology from Duke University in 1986 and completed a postdoctoral fellowship at The University of North Carolina at Chapel Hill in 1989.
“We are excited to welcome Dr. Buckheit to the Immune Therapeutics scientific team. He has demonstrated strong leadership and success in the clinical development of numerous small molecules, vaccines, and biologics, has led countless successful collaborations with federal, academic and pharmaceutical entities, and has demonstrated overall superior skill and scientific excellence in the pharmaceutical and biotechnology drug discovery field,” stated Dr. Roscoe M. Moore, Jr., DVM, MPH, Ph.D., DSc, Chair of the Board of Directors of Immune Therapeutics.
“It is an honor to join the SAB of Immune Therapeutics and become a part of an exciting and innovative platform of product development programs focused on critical issues in inflammation, cancer and infectious diseases. I look forward to playing a role in the scientific development of these products and expediting their clinical development and commercialization.”
ABOUT IMMUNE THERAPEUTICS, INC.
Immune Therapeutics Inc. is a late stage clinical stage biopharmaceutical company focused on the development and commercialization of our highly innovative immunotherapies. IMUN is a biotechnology company developing T-cell activation immunotherapies to achieve immunomodulation in patients with autoimmune and inflammatory diseases, cancer and infectious disease.
